Literature DB >> 15554770

Body mass index and future schizophrenia in Israeli male adolescents.

Mark Weiser1, Hilla Knobler, Gad Lubin, Daniella Nahon, Efrat Kravitz, Asaf Caspi, Shlomo Noy, Haim Y Knobler, Michael Davidson.   

Abstract

BACKGROUND: Compared with the general population, individuals suffering from schizophrenia are more likely to be overweight, a finding attributed to the effect of antipsychotic medications, poor nutrition, and sedentary lifestyle. As evidence accumulates indicating that some aspects of the illness manifest before the onset of psychosis and establishment of the diagnosis, it has been suggested that increased weight, like other metabolic dysfunctions, might precede active illness.
METHOD: Data on height and weight of 203,257 male adolescents assessed by the Israeli Draft Board, and followed for 2-6 years for later hospitalization for schizophrenia using the Israeli National Psychiatric Hospitalization Case Registry, were analyzed.
RESULTS: From the entire cohort, 309 (0.15%) were later hospitalized for schizophrenia (ICD-10). After removing adolescents with evidence of illness before or within 1 year of the Draft Board assessment, 204 future schizophrenia patients were available for analysis. Compared with the rest of the cohort, future schizophrenia patients had lower body mass indexes (21.24 +/- 3.3 kg/m2 vs. 21.77 +/- 3.5 kg/m2; F = 4.682, df = 1, p = .03) and weighed slightly but significantly less (64.2 +/- 11.6 kg vs. 66.3 +/- 12.0 kg; F = 6.615, df = 1, p = .01). The mean height of the future patients did not differ significantly from the mean height of the remaining cohort (173.63 +/- 6.7 cm vs. 174.40 +/- 6.9 cm; F = 2.520, df = 1, p = .112). When reanalyzing the data, controlling for physical activity and socioeconomic status, the differences between the groups remained significant.
CONCLUSION: Before the onset of illness, future schizophrenia patients are not heavier compared with their peers. This implies that the increased weight of patients with schizophrenia is related to illness effects, including the effects of antipsychotic medication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554770     DOI: 10.4088/jcp.v65n1117

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization.

Authors:  Arad Kodesh; Inbal Goldshtein; Marc Gelkopf; Iris Goren; Gabriel Chodick; Varda Shalev
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-02-07       Impact factor: 4.328

2.  Sex-dependent behavioral effects and morphological changes in the hippocampus after prenatal invasive interventions in rats: implications for animal models of schizophrenia.

Authors:  Martina von Wilmsdorff; Ulrich Sprick; Marie-Luise Bouvier; Daniela Schulz; Andrea Schmitt; Wolfgang Gaebel
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

3.  Association of measures of fetal and childhood growth with non-clinical psychotic symptoms in 12-year-olds: the ALSPAC cohort.

Authors:  K Thomas; G Harrison; S Zammit; G Lewis; J Horwood; J Heron; C Hollis; D Wolke; A Thompson; D Gunnell
Journal:  Br J Psychiatry       Date:  2009-06       Impact factor: 9.319

4.  Is dietary pattern of schizophrenia patients different from healthy subjects?

Authors:  Reza Amani
Journal:  BMC Psychiatry       Date:  2007-05-02       Impact factor: 3.630

5.  A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population.

Authors:  Kevin Williamson; Karen Kilner; Nicola Clibbens
Journal:  J Nutr Sci       Date:  2015-08-20

6.  Effects of childhood and adolescence physical activity patterns on psychosis risk-a general population cohort study.

Authors:  Elina Sormunen; Maiju M Saarinen; Raimo K R Salokangas; Risto Telama; Nina Hutri-Kähönen; Tuija Tammelin; Jorma Viikari; Olli Raitakari; Jarmo Hietala
Journal:  NPJ Schizophr       Date:  2017-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.